MiR-126: A novel route for natalizumab action?

Multiple Sclerosis

Volumn 20, Issue 10, 2014, Pages 1363-1370

  Meira, Maria ^a   Sievers, Claudia ^a   Hoffmann, Francine ^a   Derfuss, Tobias ^a   Kuhle, Jens ^a   Kappos, Ludwig ^a   Lindberg, Raija L P ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Adverse events; CD4+T lymphocytes; Mechanism of action; MiR 126; MiRNA; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy

Indexed keywords

MESSENGER RNA; MICRORNA 126; NATALIZUMAB; DNA BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; MICRORNA; MIRN126 MICRORNA, HUMAN; MONOCLONAL ANTIBODY; POU2AF1 PROTEIN, HUMAN; SPIB PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENHANCER REGION; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; IN VITRO STUDY; INHIBITION KINETICS; JC VIRUS; MALE; MULTIPLE SCLEROSIS; POU2AF1 GENE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SPI B GENE; TREATMENT DURATION; UPREGULATION; CASE CONTROL STUDY; CELL CULTURE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MICRORNAS; MIDDLE AGED; MULTIPLE SCLEROSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSFECTION; TREATMENT OUTCOME;

EID: 84907543593     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514524998     Document Type: Article

References (35)

1. Compston A and Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517.
2. Huynh JL and Casaccia P. Epigenetic mechanisms in multiple sclerosis: Implications for pathogenesis and treatment. Lancet Neurol 2013; 12: 195-206.
3. Fabian MR, Sonenberg N and Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 2010; 79: 351-379.
4. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism and function. Cell 2004; 116: 281-297.
5. Lindsay MA. MicroRNAs and the immune response. Trends Immunol 2008; 29: 343-351.
6. Farazi TA, Hoell JI, Morozov P, et al. MicroRNAs in human cancer. Adv Exp Med Biol 2013; 774: 1-20.
7. De Faria Jr O, Moore C, Kennedy T, et al. MicroRNA Dysregulation in multiple sclerosis. Frontiers Genet 2013; 3: 1-6.
8. Otaegui D, Baranzini SE, Armananzas R, et al. Differential microRNA expression in PBMC from multiple sclerosis patients. PLoS One 2009; 4: e6309.
9. Du C, Liu C, Kang J, et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nature immunol 2009; 10: 1252-1259.
10. Sondergaard HB, Hesse D, Krakauer M, et al. Differential microRNA expression in blood in multiple sclerosis. Mult Scler 2013 Dec;19(14):1849-1857.
11. Lindberg RL, Hoffmann F, Mehling M, et al. Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Europ J Immunol 2010; 40: 888-898.
12. Sievers C, Meira M, Hoffmann F, et al. Altered microRNA expression in B lymphocytes in multiple sclerosis: Towards a better understanding of treatment effects. Clin Immunol 2012; 144: 70-79.
13. Hutchinson M. Natalizumab: A new treatment for relapsing-remitting multiple sclerosis. Ther Clin Risk Manag 2007; 3: 259-268.
14. Kappos L, O'Connor PW, Polman CH, et al. Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. J Neurol 2013; 260: 1388-1395.
15. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. New Engl J Med 2012; 366: 1870-1880.
16. Lindberg RL, Achtnichts L, Hoffmann F, et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008; 194: 153-164.
17. Mattes J, Collison A, Plank M, et al. Antagonism of micro-RNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. Proc Natl Acad Sci USA 2009; 106: 18704-18709.
18. Bartholdy B, Du Roure C, Bordon A, et al. The Ets factor Spi-B is a direct critical target of the coactivator OBF-1. Proc Natl Acad Sci USA 2006; 103: 11665-11670.
19. Marshall LJ, Dunham L and Major EO. Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activity. J Gen Virol 2010; 91: 3042-3052.
20. Ban M, Booth D, Heard R, et al. Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. J Neuroimmunol 2006; 179: 108-116.
21. Waschbisch A, Atiya M, Linker RA, et al. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing-remitting multiple sclerosis. PLoS One 2011; 6: e24604.
22. Hecker Michael, Madhan Thamilarasan, Dirk Koczan, et al. MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients. Int J Molec Sci 2013; 14: 16087-16110.
23. Harris TA, Yamakuchi M, Kondo M, et al. Ets-1 and Ets-2 regulate the expression of microRNA-126 in endothelial cells. Arterioscler Thromb Vasc Biol 2010; 30: 1990-1997.
24. Moisan J, Grenningloh R, Bettelli E, et al. Ets-1 is a negative regulator of Th17 differentiation. J Exp Med 2007; 204: 2825-2835.
25. Strubin M, Newell JW and Matthias P. OBF-1, a novel B cell-specific coactivator that stimulates immunoglobulin promoter activity through association with octamer-binding proteins. Cell 1995; 80: 497-506.
26. Zwilling S, Dieckmann A, Pfisterer P, et al. Inducible expression and phosphorylation of coactivator BOB.1/OBF.1 in T cells. Science 1997; 277: 221-225.
27. Brunner C, Sindrilaru A, Girkontaite I, et al. BOB.1/OBF.1 controls the balance of TH1 and TH2 immune responses. Embo J 2007; 26: 3191-3202.
28. Yosef N, Shalek AK, Gaublomme JT, et al. Dynamic regulatory network controlling TH17 cell differentiation. Nature 2013; 496: 461-468.
29. Su GH, Ip HS, Cobb BS, et al. The Ets protein Spi-B is expressed exclusively in B cells and T cells during development. J Exp Med 1996; 184: 203-214.
30. Dorries K, Sbiera S, Drews K, et al. Association of human polyomavirus JC with peripheral blood of immunoimpaired and healthy individuals. J Neurovirol 2003; 9: 81-87.
31. Monaco MC, Atwood WJ, Gravell M, et al. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes and tonsillar stromal cells: Implications for viral latency. J Virol 1996; 70: 7004-7012.
32. Wei G, Liu CK and Atwood WJ. JC virus binds to primary human glial cells, tonsillar stromal cells, and B lymphocytes, but not to T lymphocytes. J Neurovirol 2000; 6: 127-136.
33. Chapagain ML and Nerurkar VR. Human polyomavirus JC (JCV) infection of human B lymphocytes: A possible mechanism for JCV transmigration across the blood-brain barrier. J Infect Dis 2010; 202: 184-191.
34. Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun 2011; 2: 282-291.
35. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-659.